Sarcouncil Journal of Public Administration and Management

ISSN(Online): 2945-3712

Volume- 04| Issue- 04| 2025

Review Article **Received:** 25-06-2025| **Accepted:** 16-07-2025 | **Published:** 28-08-2025

eCTD 4.0 Adoption Trends and their Impact on Pharma Regulatory Operations

Deepaben Bhavsar

Northeastern University- Boston, MA, USA

Abstract: The adoption of Electronic Common Technical Document version 4.0 (eCTD 4.0) marks a pivotal shift in pharmaceutical regulatory submissions. Designed by the ICH, eCTD 4.0 enhances interoperability, data structuring, and communication efficiency. This review examines global trends in eCTD 4.0 implementation, its impact on submission processes, and the transformation from version 3.2. Key challenges such as system integration, training, and global harmonization are evaluated, alongside the opportunities for automation, agile lifecycle management, and improved data traceability across regulatory jurisdictions.

Keywords: eCTD 4.0; electronic submissions; regulatory compliance; regulatory operations; regulatory submissions.

INTRODUCTION

Digitalization in the pharmaceutical sector continues to accelerate as companies adapt to evolving global regulatory requirements and optimize internal operations. A key milestone in this digital transformation is the adoption of the Electronic Common Technical Document version 4.0 (eCTD 4.0), developed by the International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use (ICH). This new standard represents a substantial improvement over its predecessor, offering enhanced interoperability, improved metadata granularity, and more dynamic interaction between regulatory authorities and sponsors. [International Council for Harmonisation, 2025] Unlike the preceding version, eCTD 4.0 augments structured content authoring (SCA), strong final product tagging and captioning, and a fluent dossier lifecycle, such that editing is controlled without full-fledged resubmission. [U.S. Food and Drug Administration, 2025] These characteristics help in making the processes more efficient, as well as cut down on the cycles of reviewing and make responses to the regulatory feedback more dynamic. The upgraded data repository and centralized administration suit the upward trend of the growing post-market surveillance, risk-based evaluation, and real-time data tracking. [International Council for Harmonisation, 2025; U.S. Food and Drug Administration, 2025; Freyr Solutions, 2025]

One such trend in eCTD 4.0 uptake is regional disparity in preparedness. Regulatory agencies such as the FDA of the USA, EMA, and Health Canada are on the road to full implementation, but others are integrating at a different speed. Those formats are already required by the FDA in NDAs, ANDAs, and BLAs, and have been adopted by the EMA and Health Canada. [U.S. Food and Drug Administration, 2025; European Medicines Agency, 2025; Jones, K. 2024] These organizations are driving the pharmaceutical sector worldwide beyond the old standard to the new, and the reluctant organizations are under pressure to move fast to the new standard. [European Medicines Agency, 2025; Jones, K. 2024] eCTD 4.0 also promotes cross-jurisdictional harmonization, thus leading to a reduction of duplications of regulatory submissions, and it has also led to the recognition of dossiers across jurisdictions. This is also beneficial when it comes to multinational companies that have to deal with submissions in more than one country, because it makes documentation much easier, and it also eliminates the possibility of having unnecessary customization in regions. [European Medicines Agency, 2025; Patil, N. S. *et al*., 2024] Centralized metadata and detailed tagging also make workflow automation possible, providing the foundation of a more transparent, flexible regulatory environment. [Jones, K. 2024; Patil, N. S. *et al*., 2024; U.S. Food and Drug Administration, 2024] Nevertheless, its implementation is possible only after overcoming some major obstacles. The important elements are system integration with already existing digital systems, change management, and employee training. To deal with this transformation, organizations need to invest in technology infrastructure and cross-functional collaboration. eCTD 4.0 represents not only a technological shift but also a cultural and procedural transformation, requiring stakeholders to rethink traditional regulatory submission practices. Dual submission systems maintaining both eCTD 3.2.2 and 4.0 may lead to resource inefficiencies, while early adopters stand to gain faster time-to-market, reduced compliance costs, and stronger regulatory

***Corresponding Author:** Deepaben Bhavsar

DOI-https://doi.org/10.5281/zenodo.17592948

positioning. Conversely, operational bottlenecks, data silos, and increased regulatory scrutiny could cause delays, underscoring the far-reaching impact on regulatory operations. eCTD 4.0 raises the capacity of the regulatory affairs teams to monitor, administer, and audit the aspects of the submissions through the entire product lifecycle. The leaner architecture ensures that interdepartmental coordination is promoted and the traceability and accuracy of data are enhanced, as there is a lesser chance of making mistakes and non-compliance. [European Medicines Agency, 2025; U.S. Food and Drug Administration, 2024]

In summary, eCTD 4.0 is a milestone in terms of pharmaceutical regulatory transformation. Its implementation represents a wider trend toward digital-first, data-centric operations. Considering this transition as a simple upgrade may render the process ineffective and even a challenge to business survival, especially considering that both regulators and pharmaceutical firms have set their sights on regulatory excellence in a global and digital pharmaceutical realization. Through the convergence of technology, training, and processes with the novel standard, organizations have an opportunity to not only satisfy the compliance requirements but also capitalize on the regulatory change as a competitive edge.

OVERVIEW of eCTD 4.0

The evolution of digitalization has obligated the eCTD version 4.0 to be one of the most important technological and strategic developments in the pharmaceutical regulatory activities. With eCTD 4.0, the process of dossier submission becomes data-driven and modular-based, with enhanced metadata, which is different from traditional dossier submissions that have been data-driven, deprived of modularity, and lacking metadata, as shown in Figure 1.

Structured Content Authoring, or SCA, is one of the significant newcomers supported by eCTD 4.0. Through it, companies can design reusable and modular content components sustained by clinical study reports, safety summaries, or risk management plans, which leads to faster submission time and consistency across markets globally. [International Council for Harmonisation, 2025] Improved document lifecycle management is also the direct result of the enhanced metadata schema of eCTD 4.0. Rich metadata is assigned to each component (e.g., version, purpose, connectivity of a component to other related documents), and automatically assists in validation, regulatory compliance, and auditability. [U.S. Food and Drug Administration, 2025] The standard integrates with the HL7 Regulated Product Submission (RPS) protocol, facilitating real-time, bidirectional communication between sponsors and regulatory bodies like the FDA and EMA. This improves transparency and responsiveness within the submission lifecycle. [Freyr Solutions, 2025]

eCTD 4.0 has also been designed to support granular dossier lifecycle functions (e.g., append, replace, delete) so that companies can modify their content without re-submitting whole sections. This saves a lot of redundancy. With the implementation of structured content authoring and modular submission strategies in eCTD 4.0, the absolute regulatory efficiency would be greatly enhanced, because of the lack of redundancy in the regulatory submissions, and also the rationalization of the dossier management. This will allow the pharmaceutical companies to only refresh selected modules of content and not have to reformat entire sections, thus making turnaround time and decreasing the cost of operation during term and maintenance activities.[Huma, T., & Peng, Z. 2023; Venna, S. R. 2022; International Council for Harmonisation, 2025] A key feature of eCTD 4.0 is global extensibility, allowing a core dossier to be supplemented with region-specific modules. This enables multinational companies to submit harmonized dossiers with minimal rework, improving submission efficiency and coordination across authorities such as the FDA, EMA, and Health Canada. [Sudesamithiran, N. 2023; Celegence, 2020; Veeva Systems, 2024; International Pharmaceutical Regulators Programme, 2025; Pan American Health Organization, 2021] Technically, eCTD 4.0 would provide an XML-based system that can be easily integrated into Regulatory Information Management (RIM) systems, Document Management Systems (DMS), and cloud-based systems.[Ahmed S. 2023; Pharmaceutical Commerce, 2024] It is an automated process that populates submissions via envelope content and applies internal validation rules, as well as enabling real-time regulatory intelligence dashboards. According to industry reports, the implementation of eCTD 4.0 has greatly improved the capability of regulatory teams to monitor key performance indicators (KPIs), especially in areas of compliance reporting and submission deadlines. The metadata and organizational direction of eCTD 4.0 provide a better view of the submission

Publisher: SARC Publisher

life-cycle, permitting better performance measurement and institutional reflection of regulatory operation. [Freyr Solutions, 2025; , Venna, S. R. 2022; International Council for Harmonisation, 2025; Sudesamithiran, N. 2023] eCTD 4.0 may have a more uniform and organized metadata model compared to eCTD 3.2.2, which had inconsistent or missing metadata and led to technical rejections and delays in the review process. Thus, in eCTD 4.0, with the increased validation rules, there is a lower probability of errors by application of the same validation criteria and lifecycle traceability overall. [International Council for Harmonisation, 2025] This improves compliance and provides a competitive advantage.

eCTD 4.0, together with the data-driven regulatory environments, serves as a strategic enabler. Its architecture is designed to enable it in real-time to share the data across platforms using electronic Product Information (ePI) tools, digital labeling systems, and pharmacovigilance platforms made possible by artificial intelligence (AI) tools. [Huma, T., & Peng, Z. 2023]

That said, successful adoption of eCTD 4.0 requires companies to address several critical enablers:

- **Digital infrastructure modernization**: A scalable RIM and DMS backbone is essential.
- **Process re-engineering**: Traditional submission workflows must be redesigned to align with metadata tagging, modularity, and validation structures.
- **Training and change management**: Cross-functional upskilling across RA, IT, and quality functions is crucial.

These transitions are resource-demanding in the case of small and mid-sized enterprises (SMEs). The alternative is the alliance with the IT vendor or outsourcing companies. Veeva Vault RIM, EXTEDO eCTD manager, and Lorenz docuBridge are such tools that include platforms in SaaS, which are optimized to the eCTD 4.0 standard, and with which SMEs can implement the standard without themselves having to develop it to a large extent.[1-7] eCTD 4.0 adoption transforms business by improving its regulatory agility, market sensitivity, and competitiveness. With more agencies and governments mandating deadlines, such as by 2025 with Health Canada or by 2024 with a planned transition roadmap with the FDA, increasing pressure is placed on the companies that lag behind as they begin to find difficulties in expanding operations, as well as accessing the market.



Figure 1: Overview of eCTD 4.0 Submission Process: This circular flowchart illustrates the core components and workflow of the eCTD 4.0 system, including Modules and Structure, Submission Dataset, and Submission Management. Supporting elements such as Dossier Assembly, Controlled Vocabulary, and Submission Tracking are integrated to ensure compliance, structure, and traceability in regulatory submissionsz

REGULATORY GUIDANCE AND GLOBAL HARMONIZATION

Use of eCTD 4.0 in different regions of the world is rewriting regulations and missions within the pharmaceutical industry as it has made

Publisher: SARC Publisher

submissions more interoperable, modular, and metadata-based, as shown in **Figure 2**. Although technically adopted since 2015, the rate of implementation has varied across jurisdictions and has been dictated by both the infrastructure capabilities and ambitions of the policy of those jurisdictions, and the ability to integrate with technology. Prominent regulatory agencies like the U.S. FDA, EMA, and Health Canada are at the forefront of eCTD 4.0 adoption. A long-time supporter of electronic submissions, the FDA has launched a voluntary pilot program on the use of eCTD 4.0. Sandbox initiatives in Health Canada provide real-life simulated testing environments to determine the gaps in implementation and develop institutional preparation. First outcomes showed reduced periods of review and better sponsor-regulator correspondence using two-way messaging, which is one of the main characteristics of the HL7 RPS-based framework. [International Council for Harmonisation, 2025] The agency undertook stakeholder engagement plans to facilitate sponsors and match with international best practices. [U.S. Food and Drug Administration, 2025] EMA has integrated eCTD 4.0 into its EU Telematics Strategy, and full adoption is scheduled for 2025-2027. [Synerg Biopharma, 2024; Freyr Digital, 2025] Its inclusion in SPOR and IDMP is an additional indicator of a conversion to fully operable regulatory data systems. [Freyr Solutions, 2025; U.S. Food and Drug Administration, 2025] Nevertheless, the harmonization on the global level is not complete at all. A lot of the countries in Asia, Latin America, and Africa are yet to use hybrid or paper-based systems, which have created an enormous amount of operational burdens to pharmaceutical companies with multi-jurisdictional submissions. Differences in regional modules and validation requirements still exist even among ICH members. As an example, the implementation of Module 1 has been adjusted in Health Canada so that it takes into account the national product monographs and bilingual labeling, whereas the validation requirements differ in metadata enforcement approaches by the EMA. [International Council for Harmonisation, 2025; U.S. Food and Drug Administration, 2025; U.S. Food and Drug Administration, 2025; Sudesamithiran, N. 2023; Ahmed S. 2023] Such differences compel the company to keep parallel approaches to submittals, which are usually subject to rework and involve specialized local knowledge.

Operationally, this creates a problem of increased complexity, resource consumption, and the risk of compliance problems, as there is no synchronous adoption. Pharmaceutical companies now have to maintain eCTD 3.2.2, 4.0 pipelines, which provide additional costs of document management, validation, and regulatory planning. Multi-tenance of eCTD forms and metadata mismatch are issues that have been described to be a major challenge associated with having efficient global submissions by many regulatory teams. Simultaneous maintenance of eCTD 3.2.2 and 4.0 tends to make the processes more complex, creates versioning issues, and diminishes regional harmonization, which affects overall operational efficiency.[12, 13] Practical experience among the first users indicates that the eCTD 4.0 has reduced regulatory queries largely because of improved structures of metadata and the ability to trace content. It also has a modular architecture, which enhances jurisdiction-cross-content reusability besides supporting analytics and automated compliance via Regulatory Information Management (RIM) and Document Management Systems (DMS) integration. [Venna, S. R. 2022; Celegence, 2020; Veeva Systems, 2024] These advantages are directly aligned to accelerated market entry and enhanced control of operations, particularly among firms that pre-emptively invested in digital infrastructure and re-engineering of the regulatory process. Fostering shared timelines, validation rules, and other aspects of training materials is being facilitated through international programs, including the International Pharmaceutical Regulators Program (IPRP) and APEC regulators harmonization forums, which are assisting in overcoming regulatory capability gaps. [International Pharmaceutical Regulators Programme, 2025] Even the World Health Organization (WHO) has incorporated digital readiness measures into its Global Benchmarking Tool to help agencies make a move towards an electronic submission system such as eCTD 4.0. [Pan American Health Organization, 2021]

Conclusively, the main regulators are steadily adopting eCTD 4.0. Nevertheless, the problem of operationalization in various parts of the world remains to represent a strategic challenge. In order to realize the full potential of eCTD 4.0, pharma companies should consider implementing more dynamic regulatory planning frameworks, consider building scalable digital infrastructures, and participate in international unity initiatives by

Publisher: SARC Publisher

taking part in regulatory and industry-based groups.



Figure 2: Regulatory Guidance and Global Harmonization: This diagram illustrates the foundational relationship between regulatory guidance and the process of achieving global harmonization. It emphasizes the directional flow from regional or national regulations toward a unified international framework, supporting consistency, efficiency, and global alignment in regulatory practices.

ADOPTION TRENDS AND INDUSTRY READINESS

The operational efficiency secured by the modularity structure of eCTD 4.0 and its metadata features is the main motivation for adoption. Companies that have an RIM system and structured content creation tools claim enhanced document traceability, re-use of content, and workflow automation in submissions. These previous investments in the digital application made the adoption of eCTD 4.0 with minimal disruption. [International Council for Harmonisation, 2025; U.S. Food and Drug Administration, 2025; Freyr Solutions, 2025; U.S. Food and Drug Administration, 2025; International Council for Harmonisation, 2025] Despite regulatory measures to implement eCTD 4.0, only a few industries have adopted it. Other companies are at the initial stages of planning or evaluation of the process. The companies require additional clarity and increased internal preparedness.

There are still a few obstacles to widespread adoption. The heavy implementation costs, small IT base, and system upgrades and training of personnel are issues of concern affecting small firms, particularly. Dual-format compliance is the law of the land in jurisdictions that continue to use eCTD 3.2.2 and introduces an enhanced operational burden and complex document management. In addition, the opposition to the workflow transformation and a low level of digital fluency among the regulatory teams slow down the changes at the organizational level. [International Council for Harmonisation, 2025; Celegence, 2020] Vendor ecosystem maturity also influences readiness, with eCTD 4.0 platforms now largely mature compared to earlier semi-mature systems. Scalable vendors such as Veeva offer cloud-based solutions integrated with RIM platforms, requiring companies to verify compatibility, data security, and support services before adoption. [Venna, S. R. 2022; International Council for Harmonisation, 2025; Veeva Systems, 2024] Adoption of eCTD 4.0 is challenged by geographic disparities. Companies in developed markets such as North America and Western Europe are more likely to achieve successful implementation, while developing regions face barriers, including limited infrastructure and basic regulatory support. This gap emphasizes the need for global capacity building to ensure equitable adoption of digital regulatory systems. The investment in the digital infrastructure, better compliance with the regulatory expectations, and advancing vendor-friendly technologies are the drivers of the adoption. [International Council for Harmonisation, 2025; Pharmaceutical Commerce, 2024] Professional associations such as the Regulatory Affairs Professionals Society (RAPS)

Publisher: SARC Publisher

facilitate advanced certification programs to generate the eCTD 4.0-ready talent. eCTD 4.0 adoption is at a steady pace, yet it is still determined by the digital level of maturity, the region of regulatory prospect, and the willingness to change operations of an organization. To get a better idea of the activity of the industry in the use of eCTD 4.0, it is useful to consider the actual adoption rates and the digital maturity levels in different regions and company scales. An overview of this changing scene is offered in the table below.

Table 1: Global Snapshot of eCTD 4.0 Adoption Status by Region and Company Type (as of 2024)

Region / Company Type	Adoption Status	Key Challenges
North America (Large Pharma)	Many large pharmaceutical firms in this region have begun adopting eCTD 4.0, often in pilot or early implementation phases.	Legacy system integration, high implementation costs.
North America (SMEs)	Smaller companies show slower adoption, with many still assessing feasibility and preparing internal systems.	Resource limitations and, lack of trained personnel.
European Union (All company sizes)	Moderate levels of adoption with variation across member states. Companies are aligning with EMA timelines.	Dual compliance with older eCTD versions, regulatory variation across the EU.
Asia-Pacific (All company sizes)	Initial adoption is observed, particularly among multinational firms. Local adoption varies widely by country.	Regulatory uncertainty, digital infrastructure gaps.
Latin America & Africa	Adoption remains in early discussion or pilot phases. Many companies await further regulatory clarity.	Inadequate infrastructure, training, and resource limitations.

This table illustrates the disparity in adoption rates across geographies and organizational sizes, highlighting the need for tailored implementation strategies and regional support mechanisms to ensure inclusive digital transformation.

IMPACT ON REGULATORY OPERATIONS

The switch to eCTD 4.0 is already transforming regulatory business activities by bringing in a data-centric model that has the advantage of enhancing traceability, automation, and life cycle insights. As compared to the previous versions, which were mainly aimed at unifying the submission formats, eCTD 4.0 entails the transformation of operations, in terms of moderating content reuse, structured metadata, and incorporating submissions in the form of workflows. Among the most obvious effects is on the preparation of submissions. Modular design and structured content authoring (SCA) enable companies to reuse content across dossiers and enable the assembly of submissions. This minimized duplication and the amount of manual work. Sponsors are no longer required to resubmit entire sections of documents to change just a part of the document; they can only change a clinical summary or risk management plan, and the rest does not need to be resubmitted. Operations such as append, replace, and delete are also possible to document lifecycles and make all processes involving changes to a dossier much easier to control and view. eCTD 4.0 adoption has stepped forward in regulatory automation. This integration facilitates auto-content acquisition, metadata marking, and submission packaging, which realizes quantifiable efficiency gains. Industry practice proves that it is quite possible to shorten the time of dossier preparation significantly due to the acceptance of eCTD 4.0 compliant digital platforms. [Pharmaceutical Commerce, 2024] eCTD 4.0 also enhances compliance and traceability, as well as collaborating cross-functional teams, maintaining accountability. The company can also easily retrieve document context (e.g., author, date, parent-child relationships) and records. This will facilitate audit readiness and easily execute responses. [Freyr Solutions, 2025]

The strict XML skeleton entails unified taxonomies and document typologies, enabling data standardization to allow uniformity between departments and jurisdictions. Such harmonization enhances internal data management and also the external alignment with regulators. [U.S. Food and Drug Administration, 2025; Freyr Solutions, 2025; Pharmaceutical Commerce, 2024; Patil, N. S. *et al*., 2024] Monitoring of the lifecycle and post-submission has become manageable. The

Publisher: SARC Publisher

companies are now able to monitor the progress of regulatory commitments, renew deadlines, and update labeling operations more accurately. The modular design makes the updates timely and traceable so that sanctions and violations of regulations are less likely to be overlooked. So, in conclusion, eCTD 4.0 is shifting towards more nimble, transparent, and smart regulatory processes.

CHALLENGES AND STRATEGIC CONSIDERATIONS

The adoption of eCTD 4.0 offers a series of technical, organizational, and regulatory challenges that have a direct implication on the efficiency and effectiveness of pharmaceutical regulatory operations. The adoption has been known to be a strategy-demanding process as well as a structure. The complexity of the metadata architecture is the key technical obstacle. In contrast to the previous versions, eCTD 4.0 is highly nested in XML and uses highly granular metadata, which has a higher chance of configuration and validation failures. The aspect of integrating with legacy systems is also a major obstacle. Most corporations have a hybrid IT environment with outdated (DMS) and non-standardized regulatory platforms. The process of matching them up to eCTD 4.0 involves reengineering, middleware work, or entire system redesign, which requires expertise and executive encouragement. [U.S. Food and Drug Administration, 2025]

eCTD 4.0 necessitates an organization-wide, strategy-wise restructuring of its internal regulatory processes and requires multi-functional cooperation of regulatory affairs, IT, quality, and clinical departments. It requires new standard operating procedures (SOPs), internal training, and cultural changes from document-centric to metadata and collaborative ones. The different schedules and variations in validation rules by jurisdiction often require companies to have two submission systems (eCTD v3.2.2 and 4.0). This bifurcation raises the risk of non-compliance, greater use of resources, and complexity in operation, especially in multinational submissions. [European Medicines Agency, 2025] Tactically, business enterprises need to undertake the readiness tests, which include people, processes, and platforms. Depending on the severity of the impact, phased implementations (one or more categories of products in each release) can serve to minimize disruption (roll out higher-risk categories first). The development of the capability required to allow the long-term use of the eCTD 4.0 requires training programs, concomitant simulation techniques, and inter-functional interaction. [Jones, K. 2024] Another distinctive factor is the cost. Technology, training, and process redesign may be expensive upfront. Pharmaceutical companies must also choose between implementing eCTD 4.0 in-house or outsourcing. While in-house implementation provides greater control and oversight, it demands significant internal expertise and resources. Conversely, outsourcing can accelerate deployment and reduce short-term costs, though it may introduce risks related to vendor dependency and data security. An intermediate strategy of having a hybrid that combines the internal management of strategic submissions and outsourcing of regional or large-volume dossiers will provide a balanced solution. [Patil, N. S. *et al.*, 2024] Regulator interaction is another critical factor that should be proactive. By taking technical consultations, sandboxes, and pilots with agencies such as EMA and Health Canada, the companies can learn to set the expectations, minimize risks of compliance, and ensure improvement of their reputation as a digitally mature business. [Patil, N. S. *et al.*, 2024; Sudesamithiran, N. 2023] Lastly, a sustainability planning activity is necessary. eCTD 4.0 is not a compliance project that is done once only, but the basis of future regulatory change. Businesses should be ready to undergo endless innovation, such as the use of AI, real-time review systems, and the use of electronic labeling. It will be necessary to sustain digital agility and attain success by engaging in collaborative industry initiatives on a long-term basis.

FUTURE PERSPECTIVES

As pharmaceutical companies adapt to eCTD 4.0, the foundation is being laid for a future defined by digital, data-driven regulatory operations that can forecast risk-exposed parts of the dossier, quality assurance automation, and predictive analysis of agency comments. By equipping the machine-readable content, the companies can examine the past submission performance to improve their strategy, lessen the rework, and speed up the approval turnaround. Natural language processing (NLP) technology is also being used to glean information contained in regulatory guidance and assessment reports to facilitate wiser dossier planning. The other important change is automation. The process behind metadata tagging and packages in submission is already managed through robotic process automation (RPA).

Publisher: SARC Publisher

Greater automation pipelines involving eCTD 4.0 adoption will be able to auto-populate more submission components using clinical and quality system data. Switch to Cloud-Based Integration indicates the transition of document-based and static submissions to an interactive and ongoing reception and exchange of information between the sponsors and regulators. eCTD 4.0 also ensures multinational regulatory cooperation. Projects like the Project Orbis and the ACCESS Consortium rely on standardized digital formats that would enable simultaneous product review by the different agencies. eCTD 4.0 helps more than one authority to consider the same submission simultaneously, increasing efficiency and consistency. Industries are oriented towards dynamic regulatory interaction. Regulators are experimenting with electronic updates of product labels and rapid delivery of such updates through QR codes or apps so that no delay occurs in communicating approved product information. Over time, regulatory operations will shift toward a continuous model, replacing traditional linear filings with real-time submission updates, rolling reviews, and integrated feedback between agencies and sponsors. This shift requires workforce transformation, with compliance professionals building skills in data science, digital systems, and AI alongside traditional compliance expertise. Conclusively, eCTD 4.0 is a driving force towards a wider transformation of the regulatory practice. It puts in place the earlier stage of an automated, intelligent, and harmonized world of regulator operation. Organizations that invest in digital infrastructure, cross-functional training, and advanced analytics are better positioned to be at the forefront of the changing regulatory Ecosystem.

CONCLUSION

The updates and the adoption of eCTD 4.0 are probably one of the most significant steps connected with the process of digitalization of the regulatory affairs within the pharmaceutical industry. eCTD 4.0 does not merely upgrade the file format as previously noted in this review but re-examines the preparation, structure, filing, and auditing of regulatory data on a root-and-branch basis. Beginning with the history of paper-based submissions and having reached the dynamic and automated submissions of today, the history of eCTD 4.0 shows the trends in the digitalization of innovation, data management, and cross-functional collaboration. Complete adoption and harmonization across the globe needs investment in the following categories: scalable technology platforms, effective governance models, and employee training that will enable them to align the people and processes with the new paradigm. The regulatory presentations will become intelligent, dynamic, and aligned on a global scale in the future due to AI, automation, live co-working, and interoperability with data. The eCTD NextGen, predictive submission analytics, and full digital labeling are on the horizon. With such future prospects, regulatory officers across the globe should plan for eCTD 4.0 adoption and global harmonization. This will renovate the pharmaceutical industry.

REFERENCES

1. International Council for Harmonisation. “Electronic Common Technical Document v4.0 Implementation Guide.” (2025). https://ich.org/page/ich-electronic-common-technical-document-ectd-v40
2. U.S. Food and Drug Administration. “Electronic Common Technical Document (eCTD) v4.0: FDA Regional Implementation Guide.” (2025). https://www.fda.gov/media/179700/download
3. Freyr Solutions. “What is eCTD 4.0?.” (2025). https://www.freyrsolutions.com/what-is-ectd-4.0
4. European Medicines Agency. “Annex 1 to the eCTD v4.0 EU Module 1 Specification.” (2025). https://esubmission.ema.europa.eu/tiges/docs/Annex%201%20on%20eCTD%20v4.0.pdf
5. Jones, K. "Adoption of Identification of Medicinal Products Standards in Europe: Health Authorities and Industry Insights." *European Studies–the Review of European law, Economics and Politics* 11.1 (2024): 274-299.
6. Patil, N. S., Ranjan, A., Narang, R. K., & Singh, A. "Evaluating the Imperative Role of Pre-and Post-eCTD Standards in Dossier Validation: An Inevitable Outlook." *Current Pharmaceutical Design* 30.18 (2024): 1379-1381.
7. U.S. Food and Drug Administration. “FDA Module 1 Electronic Common Technical Document (eCTD) v4.0 Implementation Guide v1.5.” (2024). https://www.fda.gov/drugs/electronic-regulatory-submission-and-review/electronic-common-technical-document-ectd-v40
8. Huma, T., & Peng, Z. "Introduction to Regulatory Affairs and Different Regulatory

Publisher: SARC Publisher

Bodies for Pharmaceutical Products and Impact of Digitalization on Regulatory Affairs." *Pharmacology & Pharmacy* 14.11 (2023): 463-477.
9. Venna, S. R. "Global Regulatory Intelligence: Leveraging Data for Faster ECTD Approvals." *Available at SSRN 5283298* (2022).
10. International Council for Harmonisation. "eCTD v4.0 orientation material." (2025). https://admin.ich.org/sites/default/files/inline-files/eCTDv4_0_Orientation_Material_v1_5.pdf
11. Sudesamithiran, N. "A review on next generation eCTD-eCTD v4. 0." *International Journal Of Drug Regulatory Affairs* 11.4 (2023): 67-73.
12. Celegence. "eCTD v4.0 overview: Benefits, challenges, and implementation." (2020). https://www.celegence.com/ectd-v4-0-overview/
13. Veeva Systems. "Plan for submission success with eCTD 4.0." (2024). https://www.veeva.com/blog/plan-for-submission-success-with-ectd-4-0/
14. International Pharmaceutical Regulators Programme. "Meetings." (2025). https://admin.iprp.global/meetings
15. Pan American Health Organization. "The WHO Global Benchmarking Tool (GBT)." (2021). https://www.paho.org/en/topics/health-services/who-global-benchmarking-tool-gbt
16. Ahmed S. "eCTD 4.0 implementation including understanding of regional differences and benefits." *IQVIA*. (2023). https://627-vjy-785.mktoweb.com/rs/627-VJY-785/images/IQVIA%20eCTD%20DIA%20Global%20Forum%20White%20Paper.pdf
17. Pharmaceutical Commerce. "eCTD 4.0 implementation: best practices." (2024). https://www.pharmaceuticalcommerce.com/view/ectd-4-0-implementation-best-practices
18. Synerg Biopharma. "Regulatory submissions: Benefits of eCTD 4.0." (2024). https://synergbiopharma.com/regulatory-submissions-benefits-of-ectd-4-0/
19. Freyr Digital. "EMA's roadmap for eCTD 4.0 – key updates and insights." (2025). https://www.freyrdigital.com/blog/emas-roadmap-for-ectd-40-key-updates-and-insi

List of Abbreviations

AI – Artificial Intelligence
ANDA – Abbreviated New Drug Application
APEC – Asia-Pacific Economic Cooperation
BLAs – Biologics License Applications
DADI – Digital Application Dataset Integration
DIA – Drug Information Association
DMS – Document Management System
eCTD – Electronic Common Technical Document
ePI – electronic Product Information
EMA – European Medicines Agency
EU – European Union
FDA – Food and Drug Administration (United States)
GBT – Global Benchmarking Tool
HL7 – Health Level Seven
ICH – International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use
IDMP – Identification of Medicinal Products
IPRP – International Pharmaceutical Regulators Programme
IT – Information Technology
KPI – Key Performance Indicator
NDA – New Drug Application
NLP – Natural Language Processing
PDF – Portable Document Format
QA – Quality Assurance
RA – Regulatory Affairs
RAPS – Regulatory Affairs Professionals Society
RIM – Regulatory Information Management

Publisher: SARC Publisher

RPA – Robotic Process Automation
RPS – Regulated Product Submission
SCA – Structured Content Authoring
SMEs – Small and Medium-sized Enterprises
SOPs – Standard Operating Procedures
SPOR – Substances, Products, Organizations, and Referentials
XML – eXtensible Markup Language
WHO – World Health Organization

Source of support: Nil; **Conflict of interest:** Nil.

Cite this article as:
Bhavsar, D. "eCTD 4.0 Adoption Trends and their Impact on Pharma Regulatory Operations." *Sarcouncil Journal of Public Administration and Management* 4.4 (2025): pp 21-30.

Publisher: SARC Publisher